Brain Cancer clinical trials in Iowa

11 actively recruiting brain cancer trials at 9 sites across Iowa.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology

NCT ID: NCT06500455

Sites in Iowa:

Mary Greeley Medical Center — Ames, Iowa
McFarland Clinic - Ames — Ames, Iowa
University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…

Sponsor: NRG Oncology

NCT ID: NCT04804644

Sites in Iowa:

Mary Greeley Medical Center — Ames, Iowa
McFarland Clinic - Ames — Ames, Iowa

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04166409

Sites in Iowa:

Blank Children's Hospital — Des Moines, Iowa
University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …

Sponsor: Jazz Pharmaceuticals

NCT ID: NCT05580562

Sites in Iowa:

University of Iowa Hospitals & Clinics — Iowa City, Iowa

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade g…

Sponsor: Day One Biopharmaceuticals, Inc.

NCT ID: NCT05566795

Sites in Iowa:

University of Iowa Hospitals Clinics — Iowa City, Iowa

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.

Sponsor: Hoffmann-La Roche

NCT ID: NCT05503264

Sites in Iowa:

University of Iowa Hospitals & Clinics — Iowa City, Iowa

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT04511013

Sites in Iowa:

Mary Greeley Medical Center — Ames, Iowa
McFarland Clinic - Ames — Ames, Iowa
McFarland Clinic - Boone — Boone, Iowa
Saint Anthony Regional Hospital — Carroll, Iowa
Iowa Methodist Medical Center — Des Moines, Iowa

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting NIH

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05099003

Sites in Iowa:

Blank Children's Hospital — Des Moines, Iowa
University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

The goal of this interventional clinical trial is to provide proof-of-principle data for the biologic activity of defactinib in combination with avutometinib in brain metastases from melanoma, and to define the potential role of the combin…

Sponsor: University of Utah

NCT ID: NCT06194929

Sites in Iowa:

University of Iowa — Iowa City, Iowa

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Iowa:

Massive Bio SYNERGY-AI site — Iowa City, Iowa

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.

Sponsor: John M. Buatti

NCT ID: NCT07447531

Sites in Iowa:

University of Iowa Health Care — Iowa City, Iowa

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20